Overview
Flumazenil is a competitive antagonist at the benzodiazepine binding site on the GABA-A receptor. Developed by Hoffmann-La Roche, it was first approved for medical use in 1987. As a specific antidote for benzodiazepine overdose, it rapidly reverses sedation without affecting other CNS depressants. In clinical practice, flumazenil is primarily administered intravenously in hospital settings. Its rapid onset (1-2 minutes) and short duration (45-90 minutes) make it particularly valuable in emergency medicine and anesthesia recovery.
Physical and Chemical Properties
Flumazenil appears as a white to off-white crystalline powder with a molecular weight of 303.29 g/mol. It demonstrates good solubility in both water and ethanol, facilitating its formulation as an injectable solution. The compound melts at 200-202°C and should be protected from light during storage. The molecule features an imidazobenzodiazepine structure that confers selective binding affinity for benzodiazepine receptors. This structural specificity prevents activity at other receptor types, contributing to its clean reversal profile without significant cardiovascular effects.
Main Applications
The primary medical use of flumazenil is the complete or partial reversal of benzodiazepine-induced sedation, particularly after surgical procedures or diagnostic tests. In emergency medicine, it serves as an antidote for benzodiazepine overdose, though caution is required with mixed overdoses. Additional applications include differential diagnosis of coma etiology and management of hepatic encephalopathy. Some practitioners use it as a diagnostic tool to confirm benzodiazepine dependence or assess benzodiazepine contribution to persistent sedation.
Safety and Storage
Flumazenil should be stored at controlled room temperature (2-8°C) in original packaging to prevent degradation. Solutions for injection should be inspected for particulate matter before administration. The drug has a relatively wide safety margin but may precipitate withdrawal in dependent patients. Important precautions include monitoring for seizure activity, especially in patients with tricyclic antidepressant co-ingestion. Resedation may occur due to flumazenil's shorter half-life compared to most benzodiazepines, necessitating repeated dosing in some cases.
B2B Procurement Guide
Pharmaceutical buyers should prioritize suppliers with GMP certification and proper cold chain logistics. Bulk purchases typically require special import permits due to flumazenil's controlled substance status in many jurisdictions. Minimum order quantities often apply for API purchases. Quality verification should include certificate of analysis review for purity (typically ≥98%) and residual solvent testing. Lead times may vary from 4-8 weeks depending on global availability. Some manufacturers offer custom formulation services for hospital-specific preparations.